Lung cancer drug trial halted early: what toripalimab Couldn't prove
NCT ID NCT04418648
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tested whether the immunotherapy drug toripalimab could help patients with limited-stage small cell lung cancer stay cancer-free longer after standard chemoradiotherapy. The study planned to enroll 170 adults aged 18-75 who had not progressed after treatment. However, the trial was terminated early, so its full potential remains unknown.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- toripalimab (an immunotherapy drug)
- What this could lead to
- If successful, this could point toward a new treatment option to delay cancer progression in patients with limited-stage small cell lung cancer after standard chemoradiotherapy.
- What could go wrong
- The study was terminated early, so results are limited. It is a phase II trial, meaning it is still early-stage and may not confirm benefit. Immunotherapy can cause immune-related side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER LIMITED STAGE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, 510060, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.